These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7954488)

  • 1. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep.
    Ramaekers JG; van Veggel LM; O'Hanlon JF
    Clin Neuropharmacol; 1994; 17 Suppl 1():S9-18. PubMed ID: 7954488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo.
    Ramaekers JG; Swijgman HF; O'Hanlon JF
    Psychopharmacology (Berl); 1992; 106 Suppl():S62-7. PubMed ID: 1546144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
    Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
    J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
    J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
    Dingemanse J; Berlin I; Payan C; Thiede HM; Puech AJ
    Psychopharmacology (Berl); 1992; 106 Suppl():S68-70. PubMed ID: 1546145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.
    Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR
    J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study.
    Lott M; Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Katz RJ; Schaettle SC
    J Clin Psychopharmacol; 1997 Aug; 17(4):255-60. PubMed ID: 9241003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
    Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
    J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G; Finberg JP; Youdim MB
    Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction.
    Philipp M; Kohnen R; Benkert O
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):149-53. PubMed ID: 8468436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of moclobemide on psychomotor performance and cognitive function.
    Fairweather DB; Kerr JS; Hindmarch I
    Int Clin Psychopharmacol; 1993; 8(1):43-7. PubMed ID: 8473720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.
    Ramaekers JG
    J Clin Psychiatry; 2003 Jan; 64(1):20-9. PubMed ID: 12590619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.
    Wingen M; Bothmer J; Langer S; Ramaekers JG
    J Clin Psychiatry; 2005 Apr; 66(4):436-43. PubMed ID: 15816785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients.
    Ramaekers JG; Ansseau M; Muntjewerff ND; Sweens JP; O'Hanlon JF
    Int Clin Psychopharmacol; 1997 May; 12(3):159-69. PubMed ID: 9248873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
    Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
    Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M; Keller HH; Kettler R
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
    Dingemanse J; Guentert T; Gieschke R; Stabl M
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):856-61. PubMed ID: 8961085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
    Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
    Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.